NCI-H446-DDP BioVector®人小细胞肺癌顺铂耐药细胞株Human Small Cell Lung Cancer cell line

BioVector® NCI-H446-DDP 细胞系是研究小细胞肺癌（SCLC）多药耐药性的核心模型，特别是针对**顺铂（Cisplatin/DDP）**的耐药机制。

• 细胞名称: NCI-H446-DDP (或 H446/DDP)

• 物种: 人类 (Homo sapiens)

• 疾病类型: 小细胞肺癌 (SCLC)

• 起源背景: 通过在亲本细胞系 NCI-H446 中通过阶梯浓度递增诱导法，结合顺铂 (DDP) 长期诱导建立的耐药株。

• 生物安全等级: 1 (建议按 BSL-2 标准处理人源样本)

• 耐药特性: 对顺铂 (Cisplatin) 具有显著的耐药性，通常表现出 5-10 倍或更高的耐药指数 (Resistance Index)。

• 多药耐药 (MDR): 往往伴随对阿霉素 (ADM)、长春新碱 (VCR) 等药物的交叉耐药。

• 分子特征:

  • 通常伴随 P-gp (ABCB1) 或 MRP1 的表达上调。

  • 凋亡抑制因子（如 Bcl-2）表达升高。

  • DNA 修复能力增强。

  
  

• 主要应用:

  • 耐药逆转实验: 筛选能逆转顺铂耐药的小分子药物或天然产物。

  • 耐药机制研究: 研究自噬、上皮-间充质转化 (EMT) 或干性因子在 SCLC 耐药中的作用。

  
  

• 形态学: 类上皮状，成团悬浮生长或松散贴壁。

• 培养基: RPMI-1640 + 10% 胎牛血清 (FBS)。

• 维持耐药性: 为了保持耐药表型，培养基中通常需定期加入低浓度的顺铂（如 1.0 - 2.0 µg/mL），但在实验前需提前 2-3 天撤药。

• 培养条件: 37 °C, 5% CO₂。

• 冷冻保存: 90% FBS + 10% DMSO。

Cell Line Datasheet - English Version

• Cell Line Name: NCI-H446-DDP (also H446/DDP)

• Species: Human (Homo sapiens)

• Disease: Small Cell Lung Cancer (SCLC)

• Origin: A cisplatin-resistant subline derived from the parental NCI-H446 cell line through chronic exposure to increasing concentrations of Cisplatin (DDP).

• Biosafety Level: 1 (BSL-2 handling recommended).

• Resistance Profile: Exhibits high resistance to Cisplatin (DDP), typically with a Resistance Index (RI) 5-10 times higher than the parental line.

• Cross-Resistance: Often shows Multidrug Resistance (MDR) to other chemotherapeutics like Adriamycin (ADM) and Vincristine (VCR).

• Molecular Profile:

  • Upregulation of efflux transporters such as P-glycoprotein (P-gp) or MRP1.

  • Enhanced DNA repair mechanisms and overexpression of anti-apoptotic proteins like Bcl-2.

  
  

• Research Applications:

  • Drug Resistance Reversal: Screening compounds that can sensitise SCLC cells back to platinum-based therapy.

  • Mechanistic Studies: Investigating the roles of autophagy, EMT, or cancer stemness in SCLC chemoresistance.

  
  

• Morphology: Epithelial-like; cells tend to grow in floating clusters or loosely adherent aggregates.

• Culture Medium: RPMI-1640 supplemented with 10% FBS.

• Maintenance of Resistance: To prevent the loss of the resistant phenotype, a maintenance dose of Cisplatin (e.g., 1.0 - 2.0 µg/mL) is often added to the culture; cells should be cultured in drug-free medium for 48–72 hours prior to use in assays.

• Incubation: 37 °C with 5% CO₂.

• Storage/Freezing: 90% FBS + 10% DMSO.

Supplier生产厂家:

BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心

BioVector NTCC Inc.

TEL: 400-800-2947

E-mail: biovector@163.com

工作微信/QQ同号: 1843439339

http://www.biovector.net